Company profile
Mineralys Therapeutics, Inc.
NASDAQ: MLYS · Healthcare · Biotechnology
PublicHQ Radnor, PACIK 0001933414Reports USD
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 61DQ —GM —SS 52
v0.1 · 35/100 weight · pillars only
↑ Altman-Z, market scale · ↓ listing tenure, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$154.7M
Employees
76
as of 2026-08-09
Market cap
$2.4B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$154.7M-$154.7M2025
Operating income-$170.6M-$170.6M2025
Total assets$661.8M$661.8M2025
Equity$646.7M$646.7M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Mineralys Therapeutics, Inc.’s financial profile?
Mineralys Therapeutics, Inc. earned -$154.7M in FY2025 net income.
Peers · Healthcare
Disc Medicine, Inc.——Kodiak Sciences Inc.——Trevi Therapeutics, Inc.——Vera Therapeutics, Inc.——Sionna Therapeutics, Inc.——Biohaven Ltd.——Key facts
CEOJon Congleton
SectorHealthcare
IndustryBiotechnology
HeadquartersRadnor, PA
ExchangeNASDAQ: MLYS
Employees76
IPO date2023-02-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.